NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

用于恒河猴 HIV/SIV 的新型重组腺病毒疫苗载体

• 批准号: 7958318
• 负责人: Dan H. Barouch
• 金额: $ 11.19万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-05-01 至 2010-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7958318
• 关键词: Adenoviruses; Computer Retrieval of Information on Scientific Projects Database; Frequencies; Funding; Grant; HIV-1 vaccine; Immunity; Institution; Macaca mulatta; New England; Primates; Recombinants; Research; Research Personnel; Resources; Safety; Serotyping; Source; United States National Institutes of Health; Virus; base; immunogenicity; novel; vector; vector vaccine; vector-based vaccine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The high frequency of pre-existing immunity to the Ad5 vector has been shown to suppress the immunogenicity and possibly impair the safety of rAd5 vaccines for HIV-1. To overcome this hurdle, we have developed novel replication-incompetent rAd vector-based vaccines derived from rare Ad serotypes and chimeric viruses.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 Ad5 载体的高频率预存免疫已被证明会抑制免疫原性，并可能损害 HIV-1 rAd5 疫苗的安全性。为了克服这一障碍，我们开发了源自​​稀有 Ad 血清型和嵌合病毒的新型无复制能力的 rAd 载体疫苗。